Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm(3): A Post Hoc Analysis from the ANANKE Study

PURPOSE: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm(3) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Senna, Gianenrico, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Schroeder, Jan Walter, Vultaggio, Alessandra, Rizzoli, Sara, Zullo, Alessandro, Boarino, Silvia, Palmisano, Marilena, Rossi, Alessandra, Vitiello, Gianfranco, Centanni, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661992/
https://www.ncbi.nlm.nih.gov/pubmed/36387835
http://dx.doi.org/10.2147/JAA.S383012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661992/
https://www.ncbi.nlm.nih.gov/pubmed/36387835
http://dx.doi.org/10.2147/JAA.S383012

Ejemplares similares